Rodrigo P Almeida1, Stephanie A Schultz2, Benjamin P Austin3, Elizabeth A Boots2, N Maritza Dowling4, Carey E Gleason3, Barbara B Bendlin2, Mark A Sager5, Bruce P Hermann6, Henrik Zetterberg7, Cynthia M Carlsson3, Sterling C Johnson2, Sanjay Asthana2, Ozioma C Okonkwo2. 1. Currently a student at Fluminense Federal University, Niteroi, Brazil2Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of. 2. Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin3Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Rese. 3. Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison. 4. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison5Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison6Department of N. 5. Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison. 6. Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison6Department of Neurology, University. 7. Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden8University of London Institute of Neurology, Queen Square, London, England.
Abstract
IMPORTANCE: Although advancing age is the strongest risk factor for the development of symptomatic Alzheimer disease (AD), recent studies have shown that there are individual differences in susceptibility to age-related alterations in the biomarkers of AD pathophysiology. OBJECTIVE: To investigate whether cognitive reserve (CR) modifies the adverse influence of age on key cerebrospinal fluid (CSF) biomarkers of AD. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional cohort of 268 individuals (211 in a cognitively normal group and 57 in a cognitively impaired group) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center participated in this study. They underwent lumbar puncture for collection of CSF samples, from which Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) were immunoassayed. In addition, we computed t-tau/Aβ42 and p-tau/Aβ42 ratios. Cognitive reserve was indexed by years of education, with 16 or more years taken to confer high reserve. Covariate-adjusted regression analyses were used to test whether the effect of age on CSF biomarkers was modified by CR. The study dates were March 5, 2010, to February 13, 2013. MAIN OUTCOMES AND MEASURES: Cerebrospinal fluid levels of Aβ42, t-tau, p-tau, t-tau/Aβ42, and p-tau/Aβ42. RESULTS: There were significant age × CR interactions for CSF t-tau (β [SE] = -6.72 [2.84], P = .02), p-tau (β [SE] = -0.71 [0.27], P = .01), t-tau/Aβ42 (β [SE] = -0.02 [0.01], P = .02), and p-tau/Aβ42 (β [SE] = -0.002 [0.001], P = .004). With advancing age, individuals with high CR exhibited attenuated adverse alterations in these CSF biomarkers compared with individuals with low CR. This attenuation of age effects by CR tended to be more pronounced in the cognitively impaired group compared with the cognitively normal group. There was evidence of a dose-response relationship such that the effect of age on the biomarkers was progressively attenuated given additional years of schooling. CONCLUSIONS AND RELEVANCE: In a sample composed of a cognitively normal group and a cognitively impaired group, higher CR was associated with a diminution of age-related alterations in CSF biomarkers of AD. This suggests one pathway through which CR might favorably alter lifetime risk for symptomatic AD.
IMPORTANCE: Although advancing age is the strongest risk factor for the development of symptomatic Alzheimer disease (AD), recent studies have shown that there are individual differences in susceptibility to age-related alterations in the biomarkers of AD pathophysiology. OBJECTIVE: To investigate whether cognitive reserve (CR) modifies the adverse influence of age on key cerebrospinal fluid (CSF) biomarkers of AD. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional cohort of 268 individuals (211 in a cognitively normal group and 57 in a cognitively impaired group) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center participated in this study. They underwent lumbar puncture for collection of CSF samples, from which Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) were immunoassayed. In addition, we computed t-tau/Aβ42 and p-tau/Aβ42 ratios. Cognitive reserve was indexed by years of education, with 16 or more years taken to confer high reserve. Covariate-adjusted regression analyses were used to test whether the effect of age on CSF biomarkers was modified by CR. The study dates were March 5, 2010, to February 13, 2013. MAIN OUTCOMES AND MEASURES: Cerebrospinal fluid levels of Aβ42, t-tau, p-tau, t-tau/Aβ42, and p-tau/Aβ42. RESULTS: There were significant age × CR interactions for CSF t-tau (β [SE] = -6.72 [2.84], P = .02), p-tau (β [SE] = -0.71 [0.27], P = .01), t-tau/Aβ42 (β [SE] = -0.02 [0.01], P = .02), and p-tau/Aβ42 (β [SE] = -0.002 [0.001], P = .004). With advancing age, individuals with high CR exhibited attenuated adverse alterations in these CSF biomarkers compared with individuals with low CR. This attenuation of age effects by CR tended to be more pronounced in the cognitively impaired group compared with the cognitively normal group. There was evidence of a dose-response relationship such that the effect of age on the biomarkers was progressively attenuated given additional years of schooling. CONCLUSIONS AND RELEVANCE: In a sample composed of a cognitively normal group and a cognitively impaired group, higher CR was associated with a diminution of age-related alterations in CSF biomarkers of AD. This suggests one pathway through which CR might favorably alter lifetime risk for symptomatic AD.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: K Liu; L B Cedres; J Stamler; A Dyer; R Stamler; S Nanas; D M Berkson; O Paul; M Lepper; H A Lindberg; J Marquardt; E Stevens; J A Schoenberger; R B Shekelle; P Collette; S Shekelle; D Garside Journal: Circulation Date: 1982-12 Impact factor: 29.690
Authors: A Assini; S Cammarata; A Vitali; M Colucci; L Giliberto; R Borghi; M L Inglese; S Volpe; S Ratto; F Dagna-Bricarelli; C Baldo; A Argusti; P Odetti; A Piccini; M Tabaton Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182
Authors: Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera Journal: Lancet Neurol Date: 2012-11-06 Impact factor: 44.182
Authors: Anna C van Loenhoud; Alle Meije Wink; Colin Groot; Sander C J Verfaillie; Jos Twisk; Frederik Barkhof; Bart van Berckel; Philip Scheltens; Wiesje M van der Flier; Rik Ossenkoppele Journal: Hum Brain Mapp Date: 2017-06-20 Impact factor: 5.038
Authors: Annie M Racine; Lindsay R Clark; Sara E Berman; Rebecca L Koscik; Kimberly D Mueller; Derek Norton; Christopher R Nicholas; Kaj Blennow; Henrik Zetterberg; Bruno Jedynak; Murat Bilgel; Cynthia M Carlsson; Bradley T Christian; Sanjay Asthana; Sterling C Johnson Journal: J Alzheimers Dis Date: 2016-10-18 Impact factor: 4.472
Authors: Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson Journal: Brain Date: 2016-06-20 Impact factor: 13.501
Authors: Janina Krell-Roesch; Prashanthi Vemuri; Anna Pink; Rosebud O Roberts; Gorazd B Stokin; Michelle M Mielke; Teresa J H Christianson; David S Knopman; Ronald C Petersen; Walter K Kremers; Yonas E Geda Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302
Authors: Andrew W Varga; Margaret E Wohlleber; Sandra Giménez; Sergio Romero; Joan F Alonso; Emma L Ducca; Korey Kam; Clifton Lewis; Emily B Tanzi; Samuel Tweardy; Akifumi Kishi; Ankit Parekh; Esther Fischer; Tyler Gumb; Daniel Alcolea; Juan Fortea; Alberto Lleó; Kaj Blennow; Henrik Zetterberg; Lisa Mosconi; Lidia Glodzik; Elizabeth Pirraglia; Omar E Burschtin; Mony J de Leon; David M Rapoport; Shou-En Lu; Indu Ayappa; Ricardo S Osorio Journal: Sleep Date: 2016-11-01 Impact factor: 5.849